# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $66 price target.
Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology co...
Truist Securities analyst Asthika Goonewardene initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Pri...
Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to $66.
Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $42 to $65.
Merus (NASDAQ:MRUS) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47...
HC Wainwright & Co. analyst Andrew Fein maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $48 to...